Immunogenicity of Guselkumab (GUS) Among Psoriasis Patients in  VOYAGE (VOY) 1&2 Studies

Kristian Reich; April Armstrong; Yaowei Zhu; Megan  Miller; Yin You; Yaung-Kaung  Shen; Ya-Wen Yang; Peter Foley; Christopher Griffiths; Bruce Strober

doi:10.25251/skin.6.supp.11

Kristian Reich

University Medical Center Hamburg-Eppendorf, Germany

April Armstrong

University of Southern California

Yaowei Zhu

Janssen Pharma

Megan Miller

Janssen Research and Development

Yin You

Janssen Research and Development

Yaung-Kaung Shen

Janssen Research and Development

Ya-Wen Yang

Janssen Pharma

Peter Foley

University of Melbourne, St. Vincent’s Hospital

Christopher Griffiths

Dermatology Centre, Salford Royal Hospital

Bruce Strober

Yale University, New Haven & Central Connecticut Dermatology Research, Cromwell, CT, USA,

Keywords

psoriasis

Abstract

N/A

References

1. Blauvelt A, et al. J Am Acad Dermatol. 2017;76(3):405-17.

2. Reich K, et al. J Am Acad Dermatol. 2017;76(3):418-31.

3. Tsakok T, et al. J Eur Acad Dermatol Venereol. 2021;35(2):329-37.

Poster PDF

Published

Mar 4, 2022

DOI https://doi.org/10.25251/skin.6.supp.11

How to Cite

Reich , K., Armstrong , A., Zhu, Y., Miller, M. ., You, Y., Shen, Y.-K. ., Yang, Y.-W., Foley, P., Griffiths, C., & Strober , B. (2022). Immunogenicity of Guselkumab (GUS) Among Psoriasis Patients in VOYAGE (VOY) 1&2 Studies. SKIN The Journal of Cutaneous Medicine, 6(2), s11. https://doi.org/10.25251/skin.6.supp.11

Issue

Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)

Section

Poster Presenations From Winter Clinical 2022 and FC PANP 2021: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Andrew Blauvelt, Anderas Wollenberg, Andrew Pink, Ketty Peris, April Armstrong , Lynda Spelman, Hidehisa Saeki, Charles Lynde, Pedro Herranz, Sebastien Barbarot, Eric Simpson, Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2) , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Jerry Bagel, Mark Lebwohl, Linda Stein Gold, J Mark Jackson, Joana Goncalves, Eugenia Levi, Kristin Callis Duffin, Bruce Strober, Efficacy of Apremilast on Quality-of-Life Measures in Patients with Moderate Plaque Psoriasis (UNVEIL Phase IV Study) , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas
Bruce Strober, Jerry Bagel, Mark Lebwohl, Linda Stein Gold, J Mark Jackson, Joana Goncalves, Eugenia Levi, Kristina Callis Duffin, Efficacy and Safety of Apremilast in Patients with Moderate Plaque Psoriasis with Lower BSA (UNVEIL Phase IV Study) , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas
Alice B Gottlieb, Bruce Strober, Diamant Tha?i, Kenneth Gordon, Sundeep Kundu, Renata Kisa, Lan Wei, Subhashis Banerjee, Joseph Merola, BMS-986165, an Oral, Selective TYK2 Inhibitor, in the Treatment of Moderate to Severe Psoriasis as Assessed by the Static Physician's Global Assessment (sPGA)/Body Surface Area (BSA) Composite Tool (sPGAxBSA), a Clinically Useful Alternative to PASI , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Robert Bissonnette, Linda Stein Gold, Leon Kircik, Stephen Tyring, Anna Tailman, April Armstrong, Efficacy of Tapinarof Cream by Body Region in Subjects With Plaque Psoriasis in a Phase 2b Randomized Controlled Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Richard B Warren, Kristian Reich, Eric L Simpson, Richard Langley, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Emilia Vacko, Melinda Gooderham, Mette Deleuran, Juan Francisco Silvestre, Stefan Weidinger, Andrew Blauvelt, 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Joe Merola, Howard Sofen, Diamant Thaci, Carle Paul, Shinichi Imafuku, Subhashis Banerjee, April Armstrong , Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy Analysis by Baseline Disease Characteristics From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Carle Paul, Craig Leonardi, Alan Menter, Kristian Reich, Linda Stein Gold, Richard B Warren, Anders Moller, Mark Lebwohl, Calcipotriol Plus Betamethasone Dipropionate Foam is Effective in Patients with Moderate-to-Severe Psoriasis: Post-Hoc Analysis of the PSO-ABLE Study , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
Bruce Strober, Yayoi Tada, Ulrich Mrowietz, Mark Lebwohl, Peter Foley, Richard G Langley, Jonathan Barker, Maggie Wang, Veerle Vanvoorden, Balint Szilagyi, Valerie Ciaravino, Carle Paul, Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Linda Stein Gold, John Selmer, Morten Præstegaard, April Armstrong , Calcipotriene and betamethasone dipropionate cream demonstrates superior efficacy in moderate plaque psoriasis compared to topical suspension: a subgroup analysis of a phase 3 trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)

<< < 1 2 3 4 5 6 7 8 9 10 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Most read articles by the same author(s)